Join us for the first-ever Cortexa Classic on Tuesday, November 11th, at the Legacy Golf Resort.

It’s been a little while since my last update, and I want to begin by thanking you for your patience. During this time, our team has been hard at work advancing our research — and I’m thrilled to share that we’ve officially launched our Phase 1 studies with our CRO partner, Concept Life Sciences in Edinburgh, Scotland.

This week, we're shifting our focus from the lab bench to the lifeline behind it all—funding the science that drives discovery.

Cortexa Progress: People First, Then Paperwork. This week, it’s all about momentum. Cortexa deepened ties with aligned…

Cortexa Therapeutics Files Provisional Patent for Dual-Targeted ALS Therapy. This week, Cortexa Therapeutics…

A New Phase of Execution: Funding, Focus, and Forward Motion: Cortexa Therapeutics is entering a pivotal stage—

This week’s focus: fiscal sponsorship, neurotoxicity, and how your support can help rewrite the future of ALS treatment.

Cortexa is filing a provisional patent and incorporating as a C-Corp, marking major milestones in our mission to fast-track

Cortexa Therapeutics shares major updates: a CNS-focused medicinal chemist joins the team, business development gains…

Neuroscience insights, startup updates, and what I’m thinking about this week. We’re moving fast. This week, we’ve been…

From Diagnosis to Discovery: Nathan Cole’s Fight Against ALS with Cortexa Therapeutics. With a mission grounded in urgency,…